GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Athersys Inc (FRA:4LSA) » Definitions » Shiller PE Ratio

Athersys (FRA:4LSA) Shiller PE Ratio : (As of May. 29, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Athersys Shiller PE Ratio?

Note: If the price history is too short, we do not calculate current Shiller PE for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Athersys Shiller PE Ratio Historical Data

The historical data trend for Athersys's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athersys Shiller PE Ratio Chart

Athersys Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Athersys Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Athersys's Shiller PE Ratio

For the Biotechnology subindustry, Athersys's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Athersys's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Athersys's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Athersys's Shiller PE Ratio falls into.



Athersys Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Athersys's E10 for the quarter that ended in Sep. 2023 is calculated as:

For example, Athersys's adjusted earnings per share data for the three months ended in Sep. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=0/129.8595*129.8595
=0.000

Current CPI (Sep. 2023) = 129.8595.

Athersys Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 -0.109 98.326 -0.144
201403 -0.108 99.695 -0.141
201406 -0.029 100.560 -0.037
201409 -0.062 100.428 -0.080
201412 -0.065 99.070 -0.085
201503 -0.148 99.621 -0.193
201506 -0.045 100.684 -0.058
201509 -0.071 100.392 -0.092
201512 0.037 99.792 0.048
201603 0.054 100.470 0.070
201606 -0.071 101.688 -0.091
201609 -0.062 101.861 -0.079
201612 -0.095 101.863 -0.121
201703 -0.056 102.862 -0.071
201706 -0.053 103.349 -0.067
201709 -0.050 104.136 -0.062
201712 -0.093 104.011 -0.116
201803 -0.065 105.290 -0.080
201806 0.043 106.317 0.053
201809 -0.060 106.507 -0.073
201812 -0.070 105.998 -0.086
201903 -0.080 107.251 -0.097
201906 -0.053 108.070 -0.064
201909 -0.073 108.329 -0.088
201912 -0.054 108.420 -0.065
202003 -0.090 108.902 -0.107
202006 -0.089 108.767 -0.106
202009 -0.093 109.815 -0.110
202012 -0.090 109.897 -0.106
202103 -0.109 111.754 -0.127
202106 -0.083 114.631 -0.094
202109 -1.496 115.734 -1.679
202112 -0.080 117.630 -0.088
202203 -2.061 121.301 -2.206
202206 -2.157 125.017 -2.241
202209 -1.162 125.227 -1.205
202212 -0.784 125.222 -0.813
202303 -0.402 127.348 -0.410
202306 -0.572 128.729 -0.577
202309 0.000 129.860 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Athersys  (FRA:4LSA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Athersys Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Athersys's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Athersys (FRA:4LSA) Business Description

Traded in Other Exchanges
Address
3201 Carnegie Avenue, Cleveland, OH, USA, 44115-2634
Athersys Inc is a biotechnology company engaged in the field of regenerative medicine. It consists of research, clinical development, manufacturing, and manufacturing process development activities. The firm's main product is Multistem cell therapy. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.

Athersys (FRA:4LSA) Headlines

No Headlines